BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VEGF Trap-Eye: Phase III data

Top-line data from the double-blind, international Phase III COPERNICUS trial in 187 patients with macular edema due to CRVO showed that monthly 2 mg intravitreal VEGF Trap-Eye met the primary endpoint of a significantly greater proportion of patients whose visual acuity improved by >=15 letters from baseline to 6 months on the ETDRS eye chart vs. sham control (56.1% vs. 12.3%, p<0.0001). VEGF Trap-Eye also met the secondary endpoint of significantly improving visual acuity as measured by mean change from baseline on the ETDRS eye chart at 6 months vs. sham control (17.3 letter gain vs. 4 letter loss, p<0.001). VEGF Trap-Eye was...

Read the full 491 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >